Skip to main content
TipRanks
Go Ultimate75% OFF

Varex Imaging (VREX) AI Stock Analysis

189 Followers
VREX

Varex Imaging

(NASDAQ:VREX)

Select Model
Rating:57Neutral
Price Target:$19.00â–²(4.97% Upside)
Action:reiterated
Date:10/29/26

The score is led by mixed financial performance: profitability has returned, but negative free cash flow and weak cash conversion are key near-term risks. Technicals are mildly supportive with improved intermediate-term trend, while valuation is a headwind given the ~35 P/E. Corporate events add some support due to the pending all-cash acquisition, but regulatory and legal contingencies temper the benefit.

Positive Factors
Installed-base demandReplacement demand tied to the installed base gives Varex a recurring component revenue stream beyond new equipment shipments. This supports business durability because customers require tubes and related parts through service cycles, while detector and software sales add exposure to upgrades and new system builds.
Negative Factors
Weak cash conversionRecent cash generation is materially weaker than accounting profitability, reducing the funds available for investment, debt reduction, and resilience during demand fluctuations. The swing from strong 2023 free cash flow to a TTM outflow indicates that working-capital, capital-spending, or other cash demands require close monitoring.

Varex Imaging (VREX) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%VREX+75.90%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$769.86M
Dividend Yield
―
Average Volume (3M)
638.47K
Price to Earnings (P/E)
34.6
Beta (1Y)
2.20
Revenue Growth
5.31%
EPS Growth
―
Country
US
Employees
2,500
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Varex Imaging Business Overview & Revenue Model

Company Description

Varex Imaging Corporation (VREX) specializes in the development and production of X-ray imaging components. Its operations are divided into two primary divisions: Medical and Industrial. Within the Medical segment, Varex provides a comprehensive rang...

How the Company Makes Money

Varex primarily makes money by selling imaging components and subsystems—most notably X-ray tubes and flat panel detectors—to OEM customers that build complete imaging systems for hospitals, clinics, and industrial inspection markets. Revenue is gene...

Varex Imaging Earnings Call Summary

Earnings Call Date:May 07, 2026(Q2-2026)|% Change Since:53.00%|Next Earnings Date:Nov 24, 2026
Earnings Call SentimentNeutral

The call highlighted solid execution on guidance, margin resilience (non‑GAAP gross margin at the high end), successful debt refinancing and clear technology and industrial pipeline momentum (CT, photon-counting, cargo systems). Offsetting these positives are modest top‑line growth (+1% YoY), a GAAP loss, margin erosion versus the prior year (down ~240 bps), elevated inventory and short‑term working capital pressures. Management provided multi-quarter visibility (annual guidance) and actions (India ramp, pricing/contract renewal levers) that could improve margins over time, but near-term growth and margin recovery remain modest.

Positive Updates

Revenue Within Guidance and Continued Demand
Q2 revenue of $216 million came in within guidance; total revenue increased 1% year-over-year, driven by medical (+2%) and industrial (+1%). Medical represented $156M (72% of total) and Industrial $60M (28%).

Negative Updates

Modest Top-Line Growth and Geographic Weakness
Overall revenue growth was modest at +1% YoY; EMEA sales declined 16% YoY, and company acknowledged lumpy industrial shipment patterns tied to prior-year large orders.

Company Guidance

Varex guided that second‑half fiscal 2026 revenue should be up roughly 3% year‑over‑year (guidance excludes any IEEPA tariff refund) and reiterated full‑year fiscal 2026 revenues of $860–$880 million with non‑GAAP EPS of $0.80–$1.00; Q3 guidance is $210–$225 million of revenue and non‑GAAP diluted EPS of $0.15–$0.30, based on non‑GAAP gross margin of 33–34%, non‑GAAP operating expenses of about $54 million, net interest and other expense of $6–$7 million, a Q3 tax rate of ~23% (full‑year tax expectation ~20%), and roughly 42 million diluted non‑GAAP shares outstanding, and management said it will resume providing annual guidance going forward.

Varex Imaging Financial Statement Overview

Summary

Income statement shows a recovery to profitability in TTM and relatively steady gross margins, but earnings have been volatile across recent years. Balance sheet leverage is improving and appears manageable, yet sensitivity to renewed earnings weakness remains. The biggest drag is cash flow: TTM operating cash flow is very low and free cash flow is negative, not supporting the return to net income and reducing financial flexibility.

Income Statement

64Positive

Balance Sheet

62Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
Income Statement
Total Revenue865.00M844.60M811.00M893.40M859.40M818.10M
Gross Profit296.90M290.50M256.90M290.30M283.50M271.50M
EBITDA93.90M3.50M62.90M94.70M114.50M104.50M
Net Income22.10M-70.30M-47.70M48.20M30.30M17.40M
Balance Sheet
Total Assets1.10B1.11B1.22B1.25B1.18B1.15B
Cash, Cash Equivalents and Short-Term Investments99.20M155.10M200.50M193.90M89.40M144.60M
Total Debt373.60M401.90M470.40M469.80M436.40M459.40M
Total Liabilities589.50M620.80M667.80M668.60M637.70M651.00M
Stockholders Equity496.60M472.60M535.10M567.70M533.40M483.30M
Cash Flow
Free Cash Flow-20.20M18.80M20.40M87.70M-4.40M77.50M
Operating Cash Flow11.30M41.70M47.30M108.40M16.90M92.60M
Investing Cash Flow-17.80M10.30M-27.50M-44.90M-48.40M-16.20M
Financing Cash Flow-31.00M-75.90M-3.30M-200.00K-23.80M-32.30M

Varex Imaging Technical Analysis

Technical Analysis SentimentNeutral
Last Price18.10

Price Trends

50DMA18.43Negative
100DMA16.29Positive
200DMA13.86Positive

Market Momentum

MACD-0.04Positive
RSI29.91Positive
STOCH16.51Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VREX, the sentiment is Neutral. The current price of 18.10 is below the 20-day moving average (MA) of 18.39, below the 50-day MA of 18.43, and above the 200-day MA of 13.86, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 29.91 is Positive, neither overbought nor oversold. The STOCH value of 16.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VREX.

Varex Imaging Risk Analysis

Varex Imaging disclosed 36 risk factors in its most recent earnings report. Varex Imaging reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.The announcement of our entry into the Merger Agreement and pendency of the Merger may result in disruptions to our business, and the Merger could divert management's attention, disrupt our relationships with third parties and employees, and result in negative publicity, customer concerns, or legal proceedings, any of which could negatively impact our operating results and ongoing business.Q2, 2026
2.Completion of the Merger is subject to the conditions contained in the Merger Agreement, including receipt of regulatory approvals, which may not be received, may take longer than expected or may impose conditions that are not presently anticipated or that cannot be met, and if these conditions are not satisfied or waived, the Merger will not be completed.Q2, 2026
3.Competition and trade compliance lawsQ2, 2026

Varex Imaging Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

VREX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GEHCGEHC79Outperform$37.51B17.5719.85%0.17%6.87%-2.26%
PHGPHG67Neutral$29.42B27.338.44%3.28%――
BRKRBRKR57Neutral$9.26B-55.56-5.15%0.33%2.16%-604.24%
VREXVREX57Neutral$769.86M34.634.60%―5.31%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ARAYARAY41Neutral$7.65M-0.45-36.60%―-12.50%5.33%
NNOXNNOX40Underperform$25.22M-0.19-94.35%―31.52%-89.07%

* Healthcare Sector Average

Performance Comparison

-50%0%50%VREXARAYBRKRPHGNNOXGEHCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
VREX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VREXVarex Imaging Corporation18.107.8676.76%
ARAYAccuray Incorporated2.44-34.55-93.40%
BRKRBruker Corporation61.3618.1542.02%
PHGKoninklijke Philips N.V.29.893.6914.10%
NNOXNano-X Imaging Ltd.0.29-2.74-90.53%
GEHCGe Healthcare Technologies Inc.81.849.6813.41%

Varex Imaging Corporate Events

M&A TransactionsShareholder Meetings

Varex Shareholders Approve Merger with Teledyne Technologies

Positive
Oct 29, 2026

On October 28, 2026, Varex Imaging held a special meeting of stockholders to vote on proposals tied to its August 10, 2026 merger agreement with Teledyne Technologies, under which Varex would be acquired via a merger and become a wholly owned subsidi...

Legal ProceedingsM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings

Varex Imaging issues supplemental disclosures amid merger lawsuits

Negative
Oct 22, 2026

On August 10, 2026, Varex Imaging agreed to be acquired by Teledyne Technologies via a merger that would make Varex a wholly owned subsidiary, with shareholders to vote on the deal at a virtual special meeting scheduled for October 28, 2026. Since th...

Business Operations and StrategyDelistings and Listing ChangesM&A Transactions

Varex Imaging Agrees to Teledyne All-Cash Acquisition

Positive
Aug 10, 2026

On August 10, 2026, Varex Imaging entered into a definitive merger agreement under which Teledyne Technologies will acquire all outstanding Varex shares for $18.90 in cash per share, valuing the deal at about $1.1 billion including equity awards and...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026